Resmed Inc (RMD) Stock Price & Analysis
Resmed Inc (RMD) rose 1.76% to USD 195.27 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
RMD last closed at USD 191.89; the session ranged USD 194.23–197.6 on volume of 790,599 shares. Market capitalization is $28.33B, with a 52-week range of USD 180.27–293.81 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 195.27 |
|---|---|
| Change | ▲ 1.76% (up) |
| Previous Close | USD 191.89 |
| Open | USD 194.27 |
| Day Range | USD 194.23 – 197.6 |
| 52-Week Range | USD 180.27 – 293.81 |
| Volume | 790,599 shares |
| Market Cap | $28.33B |
| Exchange | NYQ |
Technical Analysis (RMD)
Nexqual's technical model rates RMD "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.3 (neutral) |
| vs SMA50 | Below (USD 198.68) |
| MACD | -1.42 (negative) |
Analyst Ratings (RMD)
Wall Street analysts rate RMD "Buy" based on 15 analysts, with a mean price target of USD 248.6 (range USD 180–325), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 248.6 |
| High Target | USD 325 |
| Low Target | USD 180 |
| Buy / Hold / Sell | 7 / 10 / 1 |
Earnings (RMD)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 2.89 |
| Revenue Estimate | $1.46B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.86 vs est 2.8 ▲ beat |
| 2025-12-31 | USD 2.81 vs est 2.72 ▲ beat |
| 2025-09-30 | USD 2.55 vs est 2.5 ▲ beat |
| 2025-06-30 | USD 2.55 vs est 2.48 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (RMD)
| Total Revenue | $5.54B |
|---|---|
| Revenue Growth (YoY) | +10.80% |
| Gross Margin | +62.18% |
| Operating Margin | +35.33% |
| Profit Margin | +27.44% |
| ROE | +25.25% |
| Debt / Equity | 12.99 |
| Current Ratio | 3.01 |
| Total Cash | $1.66B |
| Total Debt | $843.17M |
| Free Cash Flow | $1.45B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (RMD)
Nexqual rates Resmed Inc's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 35% |
| Balance Sheet | Strong — $1.66B cash vs $843M debt, net cash position |
| Cash Flow | Strong — FCF $1.45B, 28% margin |
| Efficiency | Strong — ROE 25%, ROA 14.7% |
Ownership (RMD)
| Insider Ownership | +0.50% |
|---|---|
| Institutional Ownership | +69.99% |
| Shares Outstanding | 145.06M |
| Float | 144.16M |
| Short % of Float | +12.00% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (RMD)
Resmed Inc is led by Michael J. Farrell BE, MBA, SM (age 53), CEO & Chairman, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO & Chairman | Michael J. Farrell BE, MBA, SM (age 53) |
|---|---|
| Founder, Chair Emeritus & Non-Executive Director | Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD (age 83) |
| Chief Product Officer | Justin Leong (age 48) |
| Chief Financial Officer | Aaron Bloomer (age 39) |
| Chief Marketing Officer | Yvonne-Katrin Pucknat (age 49) |
Major Backers & Investors (RMD)
Notable institutional backers of Resmed Inc include Morgan Stanley, Invesco, Fidelity, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 1.85% |
| Invesco | 1.35% |
| Fidelity | 1.29% |
| First Trust Advisors LP | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.83% |
| BlackRock | 9.66% |
| State Street | 5.79% |
| BNY Mellon | 3.4% |
| Geode Capital | 3% |
| Northern Trust | 1.19% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Resmed Inc's Latest SEC 10-K Filing (filed 2025-08-08)
Key Strengths & Strategy (as disclosed to the SEC)
- Another study published in Lancet Respiratory Medicine in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 54 million Americans.
- Our leading Residential Care Software solutions are a key enabler of our Sleep and Breathing Health business, driving revenue synergies, contributing to demand generation and providing cohesion and interoperability for our AI-driven digital platform.
- Today, our Residential Care Software solutions support residential care providers serving more than 160 million individual patient accounts.
- Our quality management system is based upon the requirements of ISO 13485, Food and Drug Administration, or FDA, Quality System Regulation, or QSR, being replaced by the new FDA Quality Management System Regulation, or QMSR, effective February 2, 2026, European Medical Device Regulation, or MDR, the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell.
Partnerships
- In May 2025, we acquired VirtuOx, an IDTF, to expand our ability to partner with healthcare providers to help streamline the diagnostic process, while expanding collaboration with home medical equipment providers to efficiently support patients to start treatment. • Accelerate Market Growth through Awareness.
- If reciprocal tariffs go into widespread effect, they could have a material impact on our business and financial statements through interruption of supply chains, increases in our costs as our suppliers deal with an uncertain global trade environment or an increase or disruption of global shipping.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
| STE | STERIS plc (Ireland) | USD 214.07 | ▲ 1.66% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
| IDXX | IDEXX Laboratories, Inc. | USD 544.32 | ▼ 0.12% |
| TFX | Teleflex Incorporated | USD 132.1 | ▼ 2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.